| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8585787 | Medicina | 2016 | 6 Pages |
Abstract
The differences in consumption of drugs against osteoporosis in the Baltic countries are not very big. The consumption of antiosteoporotic drugs is not to be regarded as sufficient though. The generally low consumption of osteoporotic medicines in the Baltic countries can be attributed to the overall less than EU average wealth of the countries and less than optimal expenditure on healthcare out of the GDP.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Ott Laius, Katre Maasalu, Sulev Kõks, Aare Märtson,